Literature DB >> 18316354

Immune reconstitution and recovery of FOXP3 (forkhead box P3)-expressing T cells after transplantation for IPEX (immune dysregulation, polyendocrinopathy, enteropathy, X-linked) syndrome.

Hong Zhan1, Jo Sinclair, Stuart Adams, Catherine M Cale, Simon Murch, Lucia Perroni, Graham Davies, Persis Amrolia, Waseem Qasim.   

Abstract

Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome is a rare X-linked disorder that usually presents in early childhood with immune enteropathy, diabetes mellitus, and other autoimmune complications. The disease is caused by mutations in the forkhead box P3 gene, a transcription factor that is essential for the development and function of regulatory T cells. This population of cells plays an essential role in controlling immune responses and preventing autoimmunity. Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome is often initially treated with immunosuppressive drugs, but only allogeneic hematopoietic stem cell transplantation has offered the possibility of cure. We recently performed an unrelated donor transplant in a child with immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome by using a reduced-intensity conditioning regimen. This transplant provided a rare opportunity to gain valuable insight into the regeneration of the immune system after transplantation. Clinical recovery was associated with the emergence of regulatory T cell populations, the majority of which expressed memory phenotype markers and raised important questions about the origin and longevity of the FOXP3(+) regulatory T cell pool.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18316354     DOI: 10.1542/peds.2007-1863

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  15 in total

1.  Stable hematopoietic cell engraftment after low-intensity nonmyeloablative conditioning in patients with immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome.

Authors:  Lauri M Burroughs; Troy R Torgerson; Rainer Storb; Paul A Carpenter; David J Rawlings; Jean Sanders; Andrew M Scharenberg; Suzanne Skoda-Smith; Janet Englund; Hans D Ochs; Ann E Woolfrey
Journal:  J Allergy Clin Immunol       Date:  2010-11       Impact factor: 10.793

2.  Single centre experience of haematopoietic SCT for patients with immunodysregulation, polyendocrinopathy, enteropathy, X-linked syndrome.

Authors:  Z Nademi; M Slatter; E Gambineri; S C Mannurita; D Barge; S Hodges; S Bunn; J Thomas; B Haugk; S Hambleton; T Flood; A Cant; M Abinun; A Gennery
Journal:  Bone Marrow Transplant       Date:  2013-11-25       Impact factor: 5.483

Review 3.  Autoimmune Enteropathy: An Updated Review with Special Focus on Stem Cell Transplant Therapy.

Authors:  Zunirah Ahmed; Aamer Imdad; James A Connelly; Sari Acra
Journal:  Dig Dis Sci       Date:  2018-11-10       Impact factor: 3.199

4.  Therapeutic in vivo selection of thymic-derived natural T regulatory cells following non-myeloablative hematopoietic stem cell transplant for IPEX.

Authors:  Kimberly A Kasow; Vanessa M Morales-Tirado; David Wichlan; Sheila A Shurtleff; Allistair Abraham; Derek A Persons; Janice M Riberdy
Journal:  Clin Immunol       Date:  2011-08-02       Impact factor: 3.969

Review 5.  Mechanism-Based Strategies for the Management of Autoimmunity and Immune Dysregulation in Primary Immunodeficiencies.

Authors:  Jolan E Walter; Jocelyn R Farmer; Zsofia Foldvari; Troy R Torgerson; Megan A Cooper
Journal:  J Allergy Clin Immunol Pract       Date:  2016 Nov - Dec

6.  Profound loss of intestinal Tregs in acutely SIV-infected neonatal macaques.

Authors:  Xiaolei Wang; Huanbin Xu; Chanjuan Shen; Xavier Alvarez; David Liu; Bapi Pahar; Marion S Ratterree; Lara A Doyle-Meyers; Andrew A Lackner; Ronald S Veazey
Journal:  J Leukoc Biol       Date:  2014-12-09       Impact factor: 4.962

7.  Improving cellular therapy for primary immune deficiency diseases: recognition, diagnosis, and management.

Authors:  Linda M Griffith; Morton J Cowan; Luigi D Notarangelo; Jennifer M Puck; Rebecca H Buckley; Fabio Candotti; Mary Ellen Conley; Thomas A Fleisher; H Bobby Gaspar; Donald B Kohn; Hans D Ochs; Richard J O'Reilly; J Douglas Rizzo; Chaim M Roifman; Trudy N Small; William T Shearer
Journal:  J Allergy Clin Immunol       Date:  2009-12       Impact factor: 10.793

8.  Regulatory T cells and their role in rheumatic diseases: a potential target for novel therapeutic development.

Authors:  Diana Milojevic; Khoa D Nguyen; Diane Wara; Elizabeth D Mellins
Journal:  Pediatr Rheumatol Online J       Date:  2008-12-01       Impact factor: 3.054

Review 9.  FOXP3: genetic and epigenetic implications for autoimmunity.

Authors:  Hiroto Katoh; Pan Zheng; Yang Liu
Journal:  J Autoimmun       Date:  2013-01-11       Impact factor: 7.094

10.  FOXP3 expression following bone marrow transplantation for IPEX syndrome after reduced-intensity conditioning.

Authors:  Morna J Dorsey; A Petrovic; M R Morrow; L J Dishaw; J W Sleasman
Journal:  Immunol Res       Date:  2009       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.